7056-90-8

Usage

Uses

Used in Pharmaceutical Applications:
(5Z)-hexadec-5-enoic acid is used as a therapeutic agent for its potential health benefits, particularly in reducing inflammation and improving lipid metabolism. Its presence in various natural sources makes it a promising candidate for the development of pharmaceutical products aimed at addressing these health concerns.
Used in Nutritional Supplements:
As a naturally occurring fatty acid with potential health benefits, (5Z)-hexadec-5-enoic acid is used as an ingredient in nutritional supplements. These supplements may target individuals looking to improve their lipid metabolism and reduce inflammation through dietary means.
Used in the Food Industry:
(5Z)-hexadec-5-enoic acid, being a component of various natural sources, is used in the food industry to enhance the nutritional profile of products. Its presence can contribute to the health benefits associated with consuming these foods, making it a valuable addition to the industry's efforts to create healthier options for consumers.
Used in Cosmetics:
Given its potential anti-inflammatory properties, (5Z)-hexadec-5-enoic acid may also find application in the cosmetics industry. It could be used as an ingredient in skincare products designed to reduce inflammation and promote healthier skin.
Used in Research:
As a fatty acid with potential health benefits, (5Z)-hexadec-5-enoic acid is used in research settings to further explore its properties and applications. This may include studying its effects on inflammation, lipid metabolism, and other areas of human health.

Upstream product

• 112-44-7 undecylaldehyde 
• 17814-85-6 (4-carboxybutyl)triphenylphosphonium bromide 
• 10444-38-9 ethyl 4-cyanobutyrate 
• 22668-36-6 ethyl 5-oxopentanoate 

Downstream Products

• 89102-35-2 (5R*,6S*)-6-hydroxyhexadecan-5-olide 
• 81792-36-1 racemic erythro 6-acetoxy-5-hexadecanolide 

Relevant academic research and scientific papers

NOVEL GLYCINE TRANSPORT INHIBITORS FOR THE TREATMENT OF PAIN

The present invention relates to novel glycine transport inhibitor compounds and their use for treating pain.

Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2

It has been demonstrated previously that the endogenous compound N-arachidonyl-glycine inhibits the glycine transporter GlyT2, stimulates glycinergic neurotransmission, and provides analgesia in animal models of neuropathic and inflammatory pain. However, it is a relatively weak inhibitor with an IC50 of 9 μM and is subject to oxidation via cyclooxygenase, limiting its therapeutic value. In this paper we describe the synthesis and testing of a novel series of monounsaturated C18 and C16 acyl-glycine molecules as inhibitors of the glycine transporter GlyT2. We demonstrate that they are up to 28 fold more potent that N-arachidonyl-glycine with no activity at the closely related GlyT1 transporter at concentrations up to 30 μM. This novel class of compounds show considerable promise as a first generation of GlyT2 transport inhibitors.

SRS-A antagonists

There are described pharmacologically active compounds, useful in the treatment of allergic/inflammatory disorders involving SRS-A as causal mediator and which, in free acid form, are of formula I, STR1 in which R1 is (i) an aliphatic, saturated or unsaturated hydrocarbyl radical of up to 20 carbon atoms, unsubstituted or substituted by at least one substituent selected from halogen, hydroxy, C3-6 alkoxy, C3-6 cycloalkyl, aryl or heteroaryl, the cycloalkyl, aryl or heteroaryl being unsubstituted or substituted by at least one substituent selected from hydroxy, halogen and alkyl, alkenyl or alkynyl of up to 10 carbon atoms, (ii) cycloalkyl of 3 to 8 carbon atoms unsubstituted or substituted by alkyl, alkenyl or alkynyl of up to 16 carbon atoms, or (iii) aryl or heteroaryl, unsubstituted or substituted by hydroxyl, C1-4 alkoxy, halogen or alkyl, alkenyl or alkynyl of up to 16 carbon atoms; and R2 is (i) alkyl, cycloalkyl or alkenyl of up to 10 carbon atoms, unsubstituted or substituted by one or more substituents selected from aryl, cycloalkyl, halogen, hydroxy, NHR3 and COX, where R3 is H, C1-4 alkyl, aryl or an amino acid residue or COX, and X is OH, C1-4 alkyl, NH2 or an amino acid residue, or (ii) aryl or heteroaryl, unsubstituted or substituted by one or more substituents selected from C1-4 alkyl, C1-4 alkoxy, C2-5 acyl, halogen, hydroxy, carboxy, nitro, trihalomethyl, phenyl, C1-4 acylamino and NHR4, where R4 is hydrogen or C1-4 alkyl; and Y is --S--, --SO-- or --SO2 --, with the proviso that when --YR2 is glutathionyl, cysteinyl or cysteinylglycinyl, then R1 is other than an unsubstituted alkatetraenyl or alkapentaenyl radical of 12 to 16 carbon atoms.